AOD-9604
Anti-Obesity Drug 9604 / Tyr-hGH Fragment 177-191
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.
작용 메커니즘
Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Research protocols typically use 300-600mcg daily via subcutaneous injection, in the morning on empty stomach.
연구 노트
Clinical Research Status
AOD-9604 completed Phase 2B clinical trials for obesity conducted by Metabolic Pharmaceuticals, which failed to demonstrate statistically significant weight loss over placebo in a 24-week trial of 536 obese patients. The Australian TGA subsequently approved it with GRAS status for use in food products (2014), a controversial decision given the failed efficacy trials. It remains investigational for injectable use and is not FDA-approved for any indication.
Key Published Findings
Early studies in obese Zucker rats and mice demonstrated significant fat reduction without affecting IGF-1 levels or causing the insulin resistance associated with full-length hGH. The peptide stimulates lipolysis and inhibits lipogenesis through interaction with the beta-3 adrenergic receptor pathway. Human trial data showed that while some dose groups trended toward fat loss, the primary endpoint was not met, and the magnitude of effect did not justify further development as a standalone obesity drug.
Safety Profile
AOD-9604 demonstrated an excellent safety profile in clinical trials with no serious adverse events attributed to the drug and no effects on glucose metabolism, IGF-1, or other growth-related markers. Unlike full-length hGH, it does not cause insulin resistance, fluid retention, or joint pain. The fragment does not stimulate growth of bone, cartilage, or other tissues, confirming successful isolation of the lipolytic domain from growth-promoting activity.
Drug Interactions & Contraindications
No significant drug interactions have been documented in clinical trial data. Theoretical synergism exists with other lipolytic agents (beta-agonists, caffeine) though this has not been formally studied. No absolute contraindications have been identified beyond standard peptide precautions (pregnancy, active malignancy). The lack of IGF-1 stimulation means cancer-related contraindications applicable to GH secretagogues do not apply.
Comparison to Related Compounds
Unlike full-length hGH or GH secretagogues (GHRP-6, Ipamorelin, CJC-1295), AOD-9604 does not elevate GH or IGF-1 levels, meaning it cannot cause GH-related side effects but also cannot provide GH's anabolic, recovery, or anti-aging benefits. Compared to tirzepatide and semaglutide, its weight loss efficacy is substantially lower based on available trial data. FRAG 176-191 (without the tyrosine modification) is a related compound sometimes confused with AOD-9604.
Community Observations
Typically dosed at 250-500mcg subcutaneously daily, administered in the morning on an empty stomach to capitalize on fasted lipolysis. Often combined with other fat loss peptides or GH secretagogues to provide complementary mechanisms. Users report modest improvements in localized fat reduction over 8-12 week protocols, though expectations should be tempered by the failed Phase 2B trial results showing limited efficacy as a standalone agent.
반감기
~30-45 minutes
재조성
Bacteriostatic water (BAC)
보관
건조한 상태
Refrigerate 2-8C up to 24 months.
재조성된 상태
Refrigerate 2-8C. Use within 30 days.
미국 법적 상태
또는 알려진 이름으로
자주 묻는 질문
AOD-9604란 무엇인가요?
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.
AOD-9604는 어떻게 작용하나요?
Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.
AOD-9604의 미국 규제 현황은 어떤가요?
Research chemical (not FDA-approved)
AOD-9604의 반감기는 얼마인가요?
~30-45 minutes
AOD-9604의 다른 이름은 무엇인가요?
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기